Drug Type Small molecule drug |
Synonyms EXEL-4888, XL 888, XL888 |
Target |
Mechanism HSP90B inhibitors(Heat shock protein HSP 90-beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H37N5O3 |
InChIKeyLHGWWAFKVCIILM-HLRQEUIKSA-N |
CAS Registry1149705-71-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acidemia, Isovaleric | Phase 1 | US | 07 Jul 2017 | |
Acidemia, Isovaleric | Phase 1 | US | 07 Jul 2017 | |
Adenocarcinoma of large intestine | Phase 1 | US | 07 Jul 2017 | |
Adenocarcinoma of large intestine | Phase 1 | US | 07 Jul 2017 | |
Colorectal cancer recurrent | Phase 1 | US | 07 Jul 2017 | |
Colorectal cancer recurrent | Phase 1 | US | 07 Jul 2017 | |
Colorectal Cancer, Hereditary Nonpolyposis, Type 1 | Phase 1 | US | 07 Jul 2017 | |
Colorectal Cancer, Hereditary Nonpolyposis, Type 1 | Phase 1 | US | 07 Jul 2017 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | US | 07 Jul 2017 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | US | 07 Jul 2017 |
Phase 1 | - | wxeaoowguj(lubprgdvmr) = XL888 90 mg twice weekly combined with P 200 mg, every 3 weeks miuyaikpdi (pnhbirsefj ) View more | Positive | 23 Jan 2020 | |||
Phase 1 | 25 | uuegeqrtad(khfxibeqkv) = 3 DLTs (rash) in 12 pts were observed in the XL888 60 mg cohort, which was determined as the maximum tolerated dose ehgevikxxo (oqlmkocttv ) View more | Negative | 26 May 2019 | |||
NCT01657591 (ASCO2016) Manual | Phase 1 | Metastatic melanoma BRAF V600 Mutation | 19 | tdjgdlypep(tpdlnpgqcq) = rvkzlrrdcc lklmrubygw (sdwfrilkdb, 3.7 - 16.2) View more | Positive | 04 Jun 2016 |